HUB Organoids offers cutting-edge drug screening solutions powered by patient-derived organoid technology. Our services provide predictive insights into patient responses, enabling researchers to develop targeted therapies and improve drug development efficiency.
ONCOLOGY
Evaluate the efficacy of your compound using patient-derived tumor organoids for oncology drug development.
Link
TOXICOLOGY
Assess animal-to-human translatability in preclinical toxicology research with precision.
Link
INFLAMMATION
Test the protective effects of compounds against epithelial damage in inflammatory disease models.
Link
Clinically-relevant models to test efficacy and study resistance mechanisms.
NEW LAUNCH!
Predict therapeutic effects of antibody-drug conjugates (ADCs) with patient-specific organoid models.
Develop personalized cancer therapies by testing compounds on patient-derived tumor organoids.
Advance immuno-therapies by studying immune-tumor interactions using patient-derived organoid and immune cell co-cultures.
Investigate therapies for genetic disorders using organoid models derived from affected tissues.
Explore the impact of infectious agents on patient-derived organoids.
Can’t find what you are looking for? Leverage our state-of-the-art technology to develop new models that meet your specific needs.
NEWS AND INSIGHTS
